Top Tweets for #IMS23RF

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

MM-014 clinical trial of Daratumumab-Pd Phase 2 study. Results are encouraging given what we knew about APOLLO (PFS ~12 months) versus here 23 months. All patients had prior len (1-2 prior LOT). Remains a consideration post lenalidomide maintenance? #IMS23RF #mmsm @NBahlis

Rfonsi1's tweet photo. MM-014 clinical trial of Daratumumab-Pd Phase 2 study. Results are encouraging given what we knew about APOLLO (PFS ~12 months) versus here 23 months. All patients had prior len (1-2 prior LOT). Remains a consideration post lenalidomide maintenance?
#IMS23RF #mmsm @NBahlis https://t.co/MmYRo6Bbfu

0

11

3

3

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Final results of the CARTITUDE-1 clinical trial @YiLinMDPhD . 97 patients were treated and had a median FU of 33.4 months. #IMS23RF #mmsm https://t.co/ZEi1y4I568

Rfonsi1's tweet photo. Final results of the CARTITUDE-1 clinical trial
@YiLinMDPhD . 97 patients were treated and had a median FU of 33.4 months.
#IMS23RF #mmsm
https://t.co/ZEi1y4I568 https://t.co/WKlmYEN0YG

0

26

7

10

6K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

German GMMG-CONCEPT (Isa-KRD) study shows high rates of MRD negativity after induction, and a good number are sustained. Longer term fU is needed but the results are promising. #IMS23RF #mmsm https://t.co/vBOGOoG0xw

Rfonsi1's tweet photo. German GMMG-CONCEPT (Isa-KRD) study shows high rates of MRD negativity after induction, and a good number are sustained. Longer term fU is needed but the results are promising.
#IMS23RF #mmsm
https://t.co/vBOGOoG0xw https://t.co/yVufVj7OXH

Rfonsi1's tweet photo. German GMMG-CONCEPT (Isa-KRD) study shows high rates of MRD negativity after induction, and a good number are sustained. Longer term fU is needed but the results are promising.
#IMS23RF #mmsm
https://t.co/vBOGOoG0xw https://t.co/yVufVj7OXH

Rfonsi1's tweet photo. German GMMG-CONCEPT (Isa-KRD) study shows high rates of MRD negativity after induction, and a good number are sustained. Longer term fU is needed but the results are promising.
#IMS23RF #mmsm
https://t.co/vBOGOoG0xw https://t.co/yVufVj7OXH

Rfonsi1's tweet photo. German GMMG-CONCEPT (Isa-KRD) study shows high rates of MRD negativity after induction, and a good number are sustained. Longer term fU is needed but the results are promising.
#IMS23RF #mmsm
https://t.co/vBOGOoG0xw https://t.co/yVufVj7OXH

1

31

11

0

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

The clinical development curse against venetoclax for t(11;14) MM - How CANOVA was reported and why it is still critical patients with the t(11;14) have access to Ven. #IMS23RF #mmsm 1/x

Rfonsi1's tweet photo. The clinical development curse against venetoclax for t(11;14) MM -
How CANOVA was reported and why it is still critical patients with the t(11;14) have access to Ven.
#IMS23RF #mmsm
1/x

9

122

46

55

60K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

@fdezdelarrea gave a great presentation describing kinetics and profiling of CART in CARTITUDE-4. First steps in the correlative search for predictors. #IMS23RF #mmsm

Rfonsi1's tweet photo. @fdezdelarrea gave a great presentation describing kinetics and profiling of CART in CARTITUDE-4. First steps in the correlative search for predictors.
#IMS23RF #mmsm https://t.co/1wBItv5Mrb

Rfonsi1's tweet photo. @fdezdelarrea gave a great presentation describing kinetics and profiling of CART in CARTITUDE-4. First steps in the correlative search for predictors.
#IMS23RF #mmsm https://t.co/1wBItv5Mrb

Rfonsi1's tweet photo. @fdezdelarrea gave a great presentation describing kinetics and profiling of CART in CARTITUDE-4. First steps in the correlative search for predictors.
#IMS23RF #mmsm https://t.co/1wBItv5Mrb

Rfonsi1's tweet photo. @fdezdelarrea gave a great presentation describing kinetics and profiling of CART in CARTITUDE-4. First steps in the correlative search for predictors.
#IMS23RF #mmsm https://t.co/1wBItv5Mrb

1

5

1

0

632

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Plenary session at #IMS23RF #mmsm genomic profiling of CESAR. FISH & NGS done. Approximations to know who is at true risk of progression still need refinement and this this is of great interest. Note 50% have 1q and 5% 17p del. Most mutations subclonal

Rfonsi1's tweet photo. Plenary session at #IMS23RF #mmsm genomic profiling of CESAR. FISH & NGS done. Approximations to know who is at true risk of progression still need refinement and this this is of great interest. Note 50% have 1q and 5% 17p del. Most mutations subclonal https://t.co/utoNY2yJ6n

Rfonsi1's tweet photo. Plenary session at #IMS23RF #mmsm genomic profiling of CESAR. FISH & NGS done. Approximations to know who is at true risk of progression still need refinement and this this is of great interest. Note 50% have 1q and 5% 17p del. Most mutations subclonal https://t.co/utoNY2yJ6n

Rfonsi1's tweet photo. Plenary session at #IMS23RF #mmsm genomic profiling of CESAR. FISH & NGS done. Approximations to know who is at true risk of progression still need refinement and this this is of great interest. Note 50% have 1q and 5% 17p del. Most mutations subclonal https://t.co/utoNY2yJ6n

Rfonsi1's tweet photo. Plenary session at #IMS23RF #mmsm genomic profiling of CESAR. FISH & NGS done. Approximations to know who is at true risk of progression still need refinement and this this is of great interest. Note 50% have 1q and 5% 17p del. Most mutations subclonal https://t.co/utoNY2yJ6n

0

14

3

2

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Samer Al Hadidi, MD,MS,FACP

about 3 years ago

#IMS23 #mmsm OPTIMISMM final analysis Median follow up 64.5 months No difference in OS in ITT PFS 2 was better

HadidiSamer's tweet photo. #IMS23 #mmsm

OPTIMISMM final analysis

Median follow up 64.5 months

No difference in OS in ITT

PFS 2 was better https://t.co/0Lyws5tRDo

0

7

0

0

2K

0

2

1

0

871

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

@FelipeProsper describing Epigenomics changes in myeloma. IRF2 as essential for MM survival (increased in MM). Target genes of IRF2 are unregulated- even in precursor states. Associated with shorter OS. #IMS23RF #mmsm

Rfonsi1's tweet photo. @FelipeProsper describing Epigenomics changes in myeloma. IRF2 as essential for MM survival (increased in MM). Target genes of IRF2 are unregulated- even in precursor states. Associated with shorter OS.
#IMS23RF #mmsm https://t.co/y5vDUczTyl

Rfonsi1's tweet photo. @FelipeProsper describing Epigenomics changes in myeloma. IRF2 as essential for MM survival (increased in MM). Target genes of IRF2 are unregulated- even in precursor states. Associated with shorter OS.
#IMS23RF #mmsm https://t.co/y5vDUczTyl

Rfonsi1's tweet photo. @FelipeProsper describing Epigenomics changes in myeloma. IRF2 as essential for MM survival (increased in MM). Target genes of IRF2 are unregulated- even in precursor states. Associated with shorter OS.
#IMS23RF #mmsm https://t.co/y5vDUczTyl

Rfonsi1's tweet photo. @FelipeProsper describing Epigenomics changes in myeloma. IRF2 as essential for MM survival (increased in MM). Target genes of IRF2 are unregulated- even in precursor states. Associated with shorter OS.
#IMS23RF #mmsm https://t.co/y5vDUczTyl

0

4

1

0

306

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Dr Mala Shanmugan talking about the importance of metabolomics as a therapeutic target and it’s link to: oxidative stress, Venetoclax sensitivity,and other metabolic substrates. #IMS23RF #mmsm

Rfonsi1's tweet photo. Dr Mala Shanmugan talking about the importance of metabolomics as a therapeutic target and it’s link to: oxidative stress, Venetoclax sensitivity,and other metabolic substrates.
#IMS23RF #mmsm https://t.co/EtyTIo0Us3

0

8

1

1

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Dr. @IreneGhobrial describing her work on single cell analysis - bulk sequencing is reductionism while single cell describes heterogeneity. Can detect primary genetic changes, circulating cells, T cell diversity, T cell health and target integrity #IMS23RF #mmsm

Rfonsi1's tweet photo. Dr. @IreneGhobrial describing her work on single cell analysis - bulk sequencing is reductionism while single cell describes heterogeneity. Can detect primary genetic changes, circulating cells, T cell diversity, T cell health and target integrity
#IMS23RF #mmsm https://t.co/4EuK4OQzwd

1

29

2

1

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Very interesting work being presented regarding the origin of myeloma cells. Could they be earlier B cells? Very courageous research to try to address- but I would still have to see more. Particularly given switch translocations in IgH MM #IMS23RF #mmsm

3

33

8

1

4K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Tracking the origins of myeloma. Assessing VAF in hyperdiploid patients. Pre and postgain deletions. Great work as always by @FrancescoMaura4 group. #IMS23RF #mmsm

1

8

2

0

1K

Ramiro @DrRameza

about 3 years ago

The auditorium for the #IMS23RF #mmsm.

0

3

0

0

57

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

@FaithEDavies1 reviewing evolutionary patterns in #IMS23RF #mmsm and precursor conditions.

Rfonsi1's tweet photo. @FaithEDavies1 reviewing evolutionary patterns in #IMS23RF #mmsm and precursor conditions. https://t.co/7FVba563st

0

3

0

0

129

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

The beautiful auditorium for the #IMS23RF #mmsm. The session on the myeloma cell of origin will now start.

Rfonsi1's tweet photo. The beautiful auditorium for the #IMS23RF #mmsm. The session on the myeloma cell of origin will now start. https://t.co/Cd3FsDbzsx

1

61

3

0

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Peter Campbell from the Wellcome Trust presenting on the fascinating topic of mutations in normal tissues (albeit a bit depressing). #IMS23RF #mmsm

Rfonsi1's tweet photo. Peter Campbell from the Wellcome Trust presenting on the fascinating topic of mutations in normal tissues (albeit a bit depressing).
#IMS23RF #mmsm https://t.co/4RSkXvHnVI

0

18

3

0

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

about 3 years ago

Starting! #IMS23RF #mmsm

Rfonsi1's tweet photo. Starting! #IMS23RF #mmsm https://t.co/ZqZBIOXnVj

3

60

8

1

4K

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users